Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 3;11:1756284818798791. doi: 10.1177/1756284818798791

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Response to linaclotide in the overall population and by baseline severity at 12 weeks (a) and 52 weeks (b). Response to linaclotide was defined as a reduction in IBS-SSS overall score of ⩾50, or a reduction in score to <150 for patients with a baseline score of ⩾150.

^aIncludes six patients with IBS-C classified as mild at baseline; ^bincludes four patients with IBS-C classified as mild at baseline.

IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.